李福强,杨杰,姚怡然,刘太阳,肖源,余劲松
LI Fuqiang,YANG Jie,YAO Yiran,LIU Taiyang,XIAO Yuan,YU Jinsong

• 1:贵州医科大学附院

摘要(Abstract)：

目的:研究埃索美拉唑联合莫沙必利对食管炎部分食管动力学指标及胃蛋白酶原水平的影响。方法:86例食管炎患者均分为观察组和对照组,对照组患者给予奥美拉唑肠溶胶囊联合多潘立酮治疗,观察组患者给予埃索美拉唑肠溶胶囊联合枸橼酸莫沙必利片治疗;治疗8周时评价2组患者的临床治疗效果,比较治疗前后2组患者的食管括约肌压力、卧位反流时间比及立位反流时间比、胃蛋白酶原Ⅰ(PGⅠ)及胃蛋白酶原Ⅱ(PGⅡ)水平。结果:观察组患者治疗总有效率(93.02%)高于对照组(79.07%),差异有统计学意义(P<0.05);治疗后,2组患者的食管括约肌压力较治疗前均升高、平均卧位反流时间比、立位反流时间比、PGⅠ、PGⅡ较治疗前均降低(P<0.05),观察组各指标的改善幅度均大于对照组(P<0.05)。结论:埃索美拉唑联合莫沙必利联合治疗食管炎的疗效优于奥美拉唑肠溶胶囊联合多潘立酮,能有效改善患者的部分食管动力学及胃蛋白酶原指标。
Objective: To study the effect of esomeprazole combined with mosapride on esophageal dynamics and propepsin levels of oesophagitis patients. Methods: 86 cases of esophagitis patients in our hospital were average divided into observation group( 43 cases) and control group( 43 cases).The control group patients were treated with omeprazole combined with domperidone and colloidal bismuth pectin capsules while the observation group patients were treated with esomeprazole enteric coated capsules combined with Moxapride citrate tablets and colloidal bismuth pectin capsules. The clinical treatment effect of 2 groups of patients were assessed after eight weeks,patients of the two groups before and after treatment are compared with Esophageal sphincter pressure,horizontal reflow time ratio and vertical reflow time ratio and levels of propepsin I( PG I) and propepsin II( PG II). Results:The total effective rate( 93. 02%) of the observation group of patients with clinical treatment was higher than that of control group( 79. 07%),the difference was statistically significant( P < 0. 05). Esophageal sphincter pressure of 2 groups of patients both increased after treatment more than before treatment( P < 0. 05),the average Recumbent reflux time ratio and Vertical reversal time ratio,PG I and PG II decreased compared with before treatment( P < 0. 05),but the amplitude of the index of the observation group was improved more greatly than that of the control group( P < 0. 05). Conclusion:Esomeprazole combined with mosapride can make better effect on esophagitis than omeprazole combined with domperidone and effectively improve the patients with esophageal motility index and propepsin indexes.

关键词(KeyWords)： 食管炎,消化性;埃索美拉唑;莫沙必利;奥美拉唑;多潘立酮;食管动力学;胃蛋白酶原
esophagitis,digestibility;esomeprazole;mosapride;omeprazole;domperidone;esophageal dynamics;pepsinogen

Abstract:

Keywords:

基金项目(Foundation): 贵阳医学院附院博士基金项目

作者(Author): 李福强,杨杰,姚怡然,刘太阳,肖源,余劲松
LI Fuqiang,YANG Jie,YAO Yiran,LIU Taiyang,XIAO Yuan,YU Jinsong

DOI: 10.19367/j.cnki.1000-2707.2018.07.024

参考文献(References)：

• [1]杨四红.用雷贝拉唑和奥美拉唑对老年反流性食管炎患者进行治疗的效果对比[J].当代医药论丛,2016,7(9):182-184.
• [2]张丽宏.联用枸橼酸莫沙必利和埃索美拉唑治疗胃食管反流病的效果探究[J].当代医药论丛,2016,15(11):73-74.
• [3]黄寿坤.质子泵抑制剂联合莫沙必利治疗胃食管反流病的临床分析[J].海峡药学,2016,8(3):192-194.
• [4]杨春.埃索美拉唑联合莫沙必利治疗贲门癌术后反流性食管炎的临床疗效观察[J].中华胃食管反流病电子杂志,2015,2(3):135-137.
• [5]孙燕.莫沙必利联合兰索拉唑在反流性食管炎治疗中的应用研究[J].生物技术世界,2015,32(12):1182-1183.
• [6]陈春华.兰索拉唑对反流性食管炎患者胃蛋白酶原、食管动力学及白介素水平的影响观察[J].海南医学院学报,2013,14(8):238-240.
• [7]赵鹏.埃索美拉唑对反流性食管炎患者食管动力学指标的影响研究[J].中国医药指南,2015,12(1):177.
• [8]刘烈辉,李捷壮,陈健.黄连素对老年慢性萎缩性胃炎患者血清胃蛋白酶原及胃泌素表达的影响研究[J].中国生化药物杂志,2014,34(8):139-141.
• [9]狄艳青,郭宏华.抗菌肽根除幽门螺杆菌研究进展[J].中国实用内科杂志,2017,37(12):1115-1118.
• [10]李红,冯琴,杜春辉.糜烂性食管炎中胃蛋白酶原和胃泌素以及幽门螺杆菌抗体的检测[J].重庆医学,2012,41(31):3276-3277.
• [11]吴圣,周华,许媛.超声对重症患者胃肠与膈肌功能评价[J].中国实用内科杂志,2017,37(8):705-708.
• [12]赵鹏.埃索美拉唑对反流性食管炎患者食管动力学指标的影响研究[J].中国医药指南,2015,8(1):83-85.

文章评论(Comment)：